Teva, Intel to develop wearable machine-learning tech for Huntington’s

Teva and Intel are joining forces on a wearable device and machine-learning platform to improve the understanding and treatment of Huntington’s disease. The duo plans to deploy the platform, which will enable continuous monitoring and analysis of Huntington’s symptoms, in a substudy in an ongoing Phase II trial of the drug pridopidine in people with Huntington’s, according to a statement. They hope to launch the study in the U.S. and Canada by the end of the year. The platform comprises a smartphone and smartwatch that will measure patients’ “general functioning and movement,” the companies said in a statement. The data will then be wirelessly transmitted to a cloud-based platform developed by Intel, where it will be analyzed and translated by algorithms into quantifiable scores for motor symptom severity, according to…


Link to Full Article: Teva, Intel to develop wearable machine-learning tech for Huntington’s

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!